France
SurgeCare, founded in 2021, is at the forefront of revolutionizing precision health with its motto, "Shaping the future of precision health by decrypting the immune system." Operating out of its headquarters in France, this innovative company leverages the power of AI, Analytics, Biotechnology, Digital Health, Health Care, and Machine Learning to enhance preoperative outcomes.
At the core of SurgeCare's value proposition lies its proprietary machine learning algorithm, which integrates single-cell immune system analysis and Electronic Health Record (EHR) data. Their unique methodology involves mimicking surgical trauma in vitro, providing a revolutionary approach to predict and improve surgical outcomes. This innovation stands on more than seven years of research, primarily conducted at Stanford University.
Supporting its growth trajectory, SurgeCare secured a €5.30M Seed Round investment on 27 March 2024, backed by notable investors such as HCVC, Kima Ventures, 50 Partners, Boutique Venture Partners, Euazeo, Malakoff Humanis, and Teampact Ventures. This backing underscores a strong investor confidence in its cutting-edge solution poised to transform surgical care.
